Hong-Yan Zhang

Hong-Yan Zhang


Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2023 in Theranostics
Verified
Journal Article
Open access
PDF file
YLYuqiu Li
Yuqiu Li
MLMiao Li
Miao Li
KSKangtai Su
Kangtai Su
SZSiwen Zong
Siwen Zong
HZHong-Yan Zhang
Hong-Yan Zhang
LXLixia Xiong
Lixia Xiong
Breast cancer (BC) is one of the most commonly diagnosed cancers and the leading cause of cancer-related deaths in women worldwide. Metastasis is a major contributor to high cancer mortality and is usually the endpoint of a series of sequential and dynamic events. One of the critical events is forming a pre-metastatic niche (PMN) that occurs before macroscopic tumor cell invasion and provides a suitable environment for tumor cells to colonize and progress into metastases. Due to the unique characteristics of PMN in cancer metastasis, developing therapies to target PMN may bring new advantages in preventing cancer metastasis at an early stage. Various biological molecules, cells, and signaling pathways are altered in BC, regulating the functions of distinctive immune cells and stromal remodeling, inducing angiogenesis, and effect metabolic reprogramming and organotropism to promote PMN formation. In this review, we elucidate the multifaceted mechanisms contributing to the development of PMN in BC, discuss the characteristics of PMN, and highlight the significance of PMN in providing potential diagnostic and therapeutic strategies for BC metastasis, which may bring promising insights and foundations for future studies.

4 October 2024 in Current Research in Food Science
Verified
Journal Article
Open access
SLShengjie Li
Shengjie Li
YLYi Li
Yi Li
YCYujie Cai
Yujie Cai
ZYZizhou Yan
Zizhou Yan
JWJing Wei
Jing Wei
Tingtao ChenTingtao Chen
Tingtao Chen
Constipation is a prevalent gastrointestinal condition that significantly affects patients' physical and mental well-being, yet current treatments often lack safety and efficacy. Emerging evidence highlights the critical role of the microbiota-gut-brain axis (MBGA) in managing constipation, paving the way for probiotics as an adjuvant treatment to improve constipation symptoms. In this study, we isolated a gut probiotic strain, Lacticaseibacillus paracasei NCU-04, and investigated its improvement effects on loperamide-induced constipation in mice. We demonstrated that L. paracasei NCU-04 exhibited excellent probiotic properties, including robust growth, strong antibacterial and antioxidant capacities, and a lack of hemolytic activity in vitro. The administration of L. paracasei NCU-04 effectively improved the defecation-related indicators such as the fecal water content, time to the first black stool defecation, and intestine transit rate, suggesting enhanced gut immobility in constipated mice. Additionally, L. paracasei NCU-04 significantly reduced colon inflammation induced by loperamide. Further, L. paracasei NCU-04 increased levels of colonic motilin, 5-hydroxytryptamine (5-HT), and c-kit, while decreased that of aquaporin 3, vasoactive intestinal peptide, and peptide YY. Notably, L. paracasei NCU-04 effectively upregulated the expression of 5-HT and its receptor (i.e., 5-HT4R) in the brains of constipated mice. High-throughput sequencing revealed that L. paracasei NCU-04 restored the diversity and composition of the gut microbiota disturbed by loperamide, and significantly increased the relative abundance of Prevotella and Lactobacillus genera in the stool, while decreased that of Odoribacter, Rikenella, and Parabacteroides. Importantly, L. paracasei NCU-04 also effectively improved the depression-like behaviors associated with constipation, possibly through 5-HT mediated MGBA. These results suggest that L. paracasei NCU-04 may offer a promising approach for treating constipation and its related depressive symptoms, supporting its potential as a functional food or adjuvant therapy for human health.

17 May 2023 in Biochimica et Biophysica Acta (BBA) - Molecular Cell Research
Verified
Journal Article
Closed access
JZJunpei Zhong
Junpei Zhong
SZSiwen Zong
Siwen Zong
JWJiayang Wang
Jiayang Wang
MFMingrui Feng
Mingrui Feng
JWJie Wang
Jie Wang
LXLixia Xiong
Lixia Xiong

1 January 2023 in Computational and Structural Biotechnology Journal
Verified
Journal Article
Open access
PWPuzhen Wu
Puzhen Wu
HWHan Weng
Han Weng
WLWenting Luo
Wenting Luo
YZYi Zhan
Yi Zhan
LXLixia Xiong
Lixia Xiong
HYHai Yan
Hai Yan
Biological tissue information of the lung, such as cells and proteins, can be obtained from bronchoalveolar lavage fluid (BALF), through which it can be used as a complement to lung biopsy pathology. BALF cells can be confused with each other due to the similarity of their characteristics and differences in the way sections are handled or viewed. This poses a great challenge for cell detection. In this paper, An Improved Yolov5s Based on Transformer Backbone Network for Detection and Classification of BALF Cells is proposed, focusing on the detection of four types of cells in BALF: macrophages, lymphocytes, neutrophils and eosinophils. The network is mainly based on the Yolov5s network and uses Swin Transformer V2 technology in the backbone network to improve cell detection accuracy by obtaining global information; the C3Ghost module (a variant of the Convolutional Neural Network architecture) is used in the neck network to reduce the number of parameters during feature channel fusion and to improve feature expression performance. In addition, embedding intersection over union Loss (EIoU_Loss) was used as a bounding box regression loss function to speed up the bounding box regression rate, resulting in higher accuracy of the algorithm. The experiments showed that our model could achieve mAP of 81.29% and Recall of 80.47%. Compared to the original Yolov5s, the mAP has improved by 3.3% and Recall by 3.67%. We also compared it with Yolov7 and the newly launched Yolov8s. mAP improved by 0.02% and 2.36% over Yolov7 and Yolov8s respectively, while the FPS of our model was higher than both of them, achieving a balance of efficiency and accuracy, further demonstrating the superiority of our model.

29 January 2025 in Canadian Journal of Infectious Diseases and Medical Microbiology
Verified
Journal Article
Open access
JLJie Luo
Jie Luo
YFYilin Fang
Yilin Fang
ZQZhanghua Qi
Zhanghua Qi
FCFengyang Cui
Fengyang Cui
HHHong Hu
Hong Hu
HZHong-Yan Zhang
Hong-Yan Zhang
Diabetes mellitus (DM) is a persistent and steadily progressing metabolic condition distinguished by unregulated high levels of blood glucose. GLP1 receptor agonists have recently gained recognition as first‐line therapies in selected instances, as per the updated ADA guidelines, highlighting their efficacy not only in glycemic control but also in their broader health benefits. Nonetheless, the efficacy of GLP‐1 is limited by its brief duration of action, rapid clearance from the body, and challenges associated with subcutaneous administration. In this study, we examined the potential diabetes‐mitigating effects of a genetically engineered strain of Escherichia coli Nissle 1917 (EcN)‐GLP‐1, previously developed by our group. We utilized mouse models for both Type 1 diabetes mellitus (T1DM) and Type 2 diabetes mellitus (T2DM) to assess its efficacy. In the case of T1DM mice, the results revealed that EcN‐GLP‐1 resulted in a notable decrease in blood glucose levels. Furthermore, it exhibited a protective influence on the structural integrity of islet β ‐cells; downregulated the expressions of key inflammatory markers such as TLR‐4, p‐NF‐ κ B/NF‐ κ B, and Bax/Bcl‐2; promoted the insulin secretion; and reinstated the perturbed diversity of microbial species to a normal state. Similarly, EcN‐GLP‐1 had a pronounced impact on T2DM mice, manifesting increased presence of islet β ‐cells, decreased inflammatory response and apoptosis, and regulation of lipid metabolism in the liver. In summary, the genetically modified EcN‐GLP‐1 strain demonstrates the ability to alleviate diabetes by enhancing the islet β ‐cell population, mitigating inflammatory reactions and apoptosis, optimizing liver lipid metabolism, and reinstating a balanced microbial diversity. These findings hold promise as a potential avenue for treating DM.

1 December 2020 in Journal of Obstetrics and Gynaecology Research
Verified
Journal Article
Closed access
PDF file
MZMin Zhang
Min Zhang
Ping LiPing Li
Ping Li
XMXuemei Mao
Xuemei Mao
HZHong-Yan Zhang
Hong-Yan Zhang